Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 6/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611183 | 0.98 | HSPD1 (0.47) | CA2MAPK1HSPD1BLMHSPE1 | |
| SCHEMBL11027621 | 0.85 | HSPD1 (0.54) | CA2MAPK1HSPD1BLMHSPE1 | |
| SCHEMBL11039164 | 0.85 | HSPD1 (0.54) | CA2MAPK1HSPD1BLMHSPE1 | |
| Ammonia Solution, Strong SCHEMBL28668038 | 0.83 | HSPD1 (0.57) | CA2HSPD1BLMHSPE1MEN1 | |
| SCHEMBL28774032 | 0.82 | CA2 (0.44) | CA2MAPK1HSPD1BLMHSPE1 | |
| SCHEMBL21902155 | 0.82 | CA2 (0.44) | CA2MAPK1HSPD1BLMHSPE1 | |
| Hexane SCHEMBL6852164 | 0.82 | HSPD1 (0.42) | CA2MAPK1HSPD1BLMHSPE1 | |
| Hexane SCHEMBL5727025 | 0.82 | HSPD1 (0.42) | CA2MAPK1HSPD1BLMHSPE1 | |
| Heptane SCHEMBL6382814 | 0.80 | HSPD1 (0.45) | CA2MAPK1HSPD1BLMHSPE1 | |
| SCHEMBL1703138 | 0.79 | CA2 (0.37) | CA2MAPK1HSPD1BLMHSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| WO-2008040097-A1 | FURANONE COMPOUNDS AND LACTAM ANALOGUES THEREOF | BIOSIGNAL LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | FDPS, CYP2C19, MRPL21 | CA2 4491/4885MAPK1 4621/4885HSPD1 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.